# Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

> **NCT03737968** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 48 (actual)

## Conditions studied

- Stage II-IVB Operable HNSCC Oral Cavity
- Hypopharynx
- Oropharynx
- Larynx

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** durvalumab + tremelimumab

## Key facts

- **NCT ID:** NCT03737968
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-02
- **Primary completion:** 2023-10
- **Final completion:** 2023-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03737968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03737968, "Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03737968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*